Genentech Could Regain the Blindness-Related Disease Market with New Treatment
Published: Feb 12, 2021 By Kate Goodwin After announcing topline data from two identical Phase III trials, Roche’s Genentech has doubled down on data and is now Faricimab is an injectable treatment to maintain the vision of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). These are two of the leading causes of blindness with nAMD responsible for 90% of all blindness resulting from AMD. Genetech’s Lucentis was the first FDA-approved drug proven to restore sight in nAMD patients. Since 2006 it had been a game-chang...
Source: biospace.com